PharmaBlock Sciences Nanjing Inc Class A Market Cap ($1.62 Billion)
Market Cap & Net Worth: PharmaBlock Sciences Nanjing Inc Class A (300725)
PharmaBlock Sciences Nanjing Inc Class A market cap. PharmaBlock Sciences Nanjing Inc Class A (SHE:300725) has a market capitalization of $1.62 Billion (CN¥11.05 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #6729 globally and #1334 in its home market, demonstrating a 14.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaBlock Sciences Nanjing Inc Class A's stock price CN¥47.25 by its total outstanding shares 233807341 (233.81 Million). Also see 300725 operating cash flow for how efficiently the company converts equity into cash flow.
PharmaBlock Sciences Nanjing Inc Class A Market Cap History (2017–2026)
PharmaBlock Sciences Nanjing Inc Class A market cap history from 2017 to 2026. Data shows growth from $1.51 Billion to $1.62 Billion (25.14% CAGR). Check PharmaBlock Sciences Nanjing Inc Class A stock price for real-time trading data and today's change.
PharmaBlock Sciences Nanjing Inc Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaBlock Sciences Nanjing Inc Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PharmaBlock Sciences Nanjing Inc Class A annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.67x
PharmaBlock Sciences Nanjing Inc Class A's market cap is 0.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.18x
PharmaBlock Sciences Nanjing Inc Class A's market cap is 7.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.51 Billion | $273.25 Million | $67.18 Million | 5.53x | 22.48x |
| 2018 | $1.07 Billion | $478.25 Million | $133.36 Million | 2.24x | 8.02x |
| 2019 | $1.77 Billion | $662.23 Million | $152.07 Million | 2.67x | 11.64x |
| 2020 | $3.58 Billion | $1.02 Billion | $184.21 Million | 3.50x | 19.44x |
| 2021 | $4.80 Billion | $1.20 Billion | $486.56 Million | 3.99x | 9.86x |
| 2022 | $2.72 Billion | $1.59 Billion | $314.22 Million | 1.71x | 8.66x |
| 2023 | $1.33 Billion | $1.73 Billion | $197.36 Million | 0.77x | 6.74x |
| 2024 | $1.15 Billion | $1.69 Billion | $219.54 Million | 0.68x | 5.24x |
| 2025 | $1.32 Billion | $1.97 Billion | $183.74 Million | 0.67x | 7.18x |
Competitor Companies of 300725 by Market Capitalization
Companies near PharmaBlock Sciences Nanjing Inc Class A in the global market cap rankings as of November 5, 2026. Also see 300725 total asset value for a full breakdown of the balance sheet.
Key companies related to PharmaBlock Sciences Nanjing Inc Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of PharmaBlock Sciences Nanjing Inc Class A (2017–2026)
Market capitalization of PharmaBlock Sciences Nanjing Inc Class A from 2017 to today. Between 2017 and today, PharmaBlock Sciences Nanjing Inc Class A's market cap moved from $1.51 Billion to $ 1.62 Billion, with a yearly change of 25.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.62 Billion | +22.54% |
| 2025 | CN¥1.32 Billion | +14.76% |
| 2024 | CN¥1.15 Billion | -13.55% |
| 2023 | CN¥1.33 Billion | -51.12% |
| 2022 | CN¥2.72 Billion | -43.31% |
| 2021 | CN¥4.80 Billion | +34.00% |
| 2020 | CN¥3.58 Billion | +102.35% |
| 2019 | CN¥1.77 Billion | +65.52% |
| 2018 | CN¥1.07 Billion | -29.17% |
| 2017 | CN¥1.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of PharmaBlock Sciences Nanjing Inc Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.62 Billion USD |
| MoneyControl | $1.62 Billion USD |
| MarketWatch | $1.62 Billion USD |
| marketcap.company | $1.62 Billion USD |
| Reuters | $1.62 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more